IDEAYA reports 57% eye preservation rate in darovasertib trial for primary uveal melanoma
IDYA•IDEAYA Biosciences reported a 57% eye preservation rate in a darovasertib trial for primary uveal melanoma. Updated results from three uveal melanoma trials are scheduled for presentation at ESMO on October 24, 2026.
1. Updated trial results
IDEAYA Biosciences announced updated results from three darovasertib uveal melanoma trials for presentation at ESMO on October 24, 2026. In the neoadjuvant OptimUM-09 trial, darovasertib shrank primary tumors, helping patients preserve their eyes or reduce planned radiation exposure to critical eye structures; safety profiles remained manageable in OptimUM-09 and OptimUM-01.
